

Rationale for Initiation, Continuation and Discontinuation (RICaD)

Rivaroxaban ▼

- For the treatment of deep vein thrombosis and prevention of recurrent deep vein thrombosis and pulmonary embolism (NICE TA 261)
- For treating pulmonary embolism and preventing recurrent venous thromboembolism (NICE TA 287)

This document supports the use and transfer of an agent which is classified as **AMBER**.

It is intended for completion by specialist in order to give Primary Care prescribers a clear indication of the reason for recommending an **AMBER** medication together with suggested criteria for its subsequent continuation or discontinuation. This RICaD should be provided as a supplement to the specialist's clinical letter.

Patient details		GP details		Specialist details	
Name		GP name	Dr	Specialist name	
PID		GP address		I confirm that this patient is eligible to receive rivaroxaban under the restrictions listed below	
DOB				Signature	
Patient address				Date	
				Contact details	

Rationale for Choice

Relevant Diagnosis:	DVT/PE	
Agreed	NICE TA 261 <input type="checkbox"/>	NICE TA 287 <input type="checkbox"/>
Indication(s) for inclusion in the BSSE APC Formulary:	Rivaroxaban is recommended as an option for treating deep vein thrombosis and preventing recurrent deep vein thrombosis and pulmonary embolism after a diagnosis of acute deep vein thrombosis in adults	Rivaroxaban is recommended as an option for treating pulmonary embolism and preventing recurrent deep vein thrombosis and pulmonary embolism in adults.
	Indication Acute deep vein thrombosis <input type="checkbox"/> Prevention of recurrent DVT and pulmonary embolism (PE) following an acute DVT in adults. <input type="checkbox"/> Treatment of acute PE <input type="checkbox"/> Period of anticoagulation proposed 3 months <input type="checkbox"/> Other <input type="checkbox"/> please specify..... SPC states: Experience with rivaroxaban in this indication for more than 12 months is limited.	

Please turnover to continue.....

Rationale for Choice cont...

<p>Reason why rivaroxaban has been chosen in preference to drugs without Formulary restrictions:</p>	<p>Specialists please type text below and check boxes: I can confirm that an informed discussion about the benefits and risks of rivaroxaban compared with warfarin has taken place with the patient. Rivaroxaban has been selected for this patient because:</p> <p><input type="checkbox"/> Commissioned in DVT pathway in locality</p> <p><input type="checkbox"/> Patient has an allergic reaction/intolerance of coumarins (warfarin, phenindione, sinthrome)</p> <p><input type="checkbox"/> Patient has an important and unavoidable drug interaction(s) that favour rivaroxaban over warfarin</p> <p><input type="checkbox"/> Patient would find it difficult to cope with a variable dose regimen and subsequent monitoring, but is able to comply with a fixed dose drug regime.</p> <p><input type="checkbox"/> Patient has had a significant bleed on warfarin and bleed is associated with poor INR control in despite patient being adherent with prescribed medication.</p> <p><input type="checkbox"/> Poor INR control (e.g. more than 2 INRs >8.0 or more than 3 INRs >5.0 in 6 months)</p> <p><input type="checkbox"/> Poor TTR (Time in therapeutic range). List TTR value:</p> <p><input type="checkbox"/> Patients who, following informed discussion of risks and benefits of rivaroxaban and warfarin, request rivaroxaban as their preferred choice in terms of a favourable lifestyle in comparison to warfarin</p>
<p>Special precautions</p>	<p>Contraindications</p> <ul style="list-style-type: none"> • Hypersensitivity to the active substance or to any of the excipients listed • Active clinically significant bleeding. • Lesion or condition, if considered to be a significant risk for major bleeding. This may include current or recent gastrointestinal ulceration, presence of malignant neoplasms at high risk of bleeding, recent brain or spinal injury, recent brain, spinal or ophthalmic surgery, recent intracranial haemorrhage, known or suspected oesophageal varices, arteriovenous malformations, vascular aneurysms or major intraspinal or intracerebral vascular abnormalities. • Concomitant treatment with any other anticoagulants e.g. unfractionated heparin (UFH), low molecular weight heparins (enoxaparin, dalteparin, etc.), heparin derivatives (fondaparinux, etc.), oral anticoagulants (warfarin, dabigatran etexilate, apixaban, etc.) except under specific circumstances of switching anticoagulant therapy or when UFH is given at doses necessary to maintain an open central venous or arterial catheter • Hepatic disease associated with coagulopathy and clinically relevant bleeding risk including cirrhotic patients with Child-Pugh B and C • Pregnancy and breast feeding <p>Cautions</p> <p><u>Haemorrhagic risk</u></p> <p>Several sub-groups of patients, as detailed below, are at increased risk of bleeding. These patients are to be carefully monitored for signs and symptoms of bleeding complications and anaemia after initiation of treatment This may be done by regular physical examination of the patients, close observation of the surgical wound drainage and periodic measurements of haemoglobin.</p> <p>Any unexplained fall in haemoglobin or blood pressure should lead to a search for a bleeding site.</p> <p>Although treatment with rivaroxaban does not require routine monitoring of exposure, rivaroxaban levels measured with a calibrated quantitative anti-factor Xa assay may be useful in exceptional situations where knowledge of rivaroxaban exposure may help to inform clinical decisions, e.g., overdose and emergency surgery</p> <p><u>Renal impairment</u></p> <p>In patients with severe renal impairment (creatinine clearance < 30 ml/min) rivaroxaban plasma levels may be significantly increased (1.6-fold on average) which may lead to an increased bleeding risk. Rivaroxaban is to be used with caution in patients with creatinine clearance 15-29 ml/min. Use is not recommended in patients with creatinine clearance < 15 ml/min</p> <p>In patients with moderate renal impairment (creatinine clearance 30-49 ml/min) concomitantly receiving other medicinal products which increase rivaroxaban plasma concentrations rivaroxaban is to be used with caution</p> <p><u>Elderly population</u></p> <p>Increasing age may increase haemorrhagic risk.</p> <p><u>Interaction with other medicinal products</u></p> <p>The use of rivaroxaban is not recommended in patients receiving concomitant systemic treatment with azole-antimycotics (such as ketoconazole, itraconazole, voriconazole and posaconazole) or HIV protease inhibitors (e.g. ritonavir). These active substances are strong inhibitors of both CYP3A4 and P-gp and therefore may increase rivaroxaban plasma concentrations to a clinically relevant degree (2.6-fold on average) which may lead to an increased bleeding risk</p> <p>Care is to be taken if patients are treated concomitantly with medicinal products affecting haemostasis such as non-steroidal anti-inflammatory medicinal products (NSAIDs), acetylsalicylic acid (ASA) and platelet aggregation inhibitors. For patients at risk of ulcerative gastrointestinal disease an appropriate prophylactic treatment may be considered</p> <p><u>Other haemorrhagic risk factors</u></p> <p>As with other antithrombotics, rivaroxaban is to be used with caution in patients with an increased bleeding risk such as:</p> <ul style="list-style-type: none"> • congenital or acquired bleeding disorders

	<ul style="list-style-type: none"> • uncontrolled severe arterial hypertension • other gastrointestinal disease <u>without active ulceration</u> that can potentially lead to bleeding complications (e.g. inflammatory bowel disease, oesophagitis, gastritis and gastroesophageal reflux disease) • vascular retinopathy • bronchiectasis or history of pulmonary bleeding. <p><u>Dosing recommendations before and after invasive procedures and surgical intervention other than elective hip or knee replacement surgery</u></p> <p>If an invasive procedure or surgical intervention is required, rivaroxaban should be stopped at least 24 hours before the intervention, if possible and based on the clinical judgement of the physician.</p> <p>If the procedure cannot be delayed the increased risk of bleeding should be assessed against the urgency of the intervention.</p> <p>Rivaroxaban should be restarted as soon as possible after the invasive procedure or surgical intervention provided the clinical situation allows and adequate haemostasis has been established as determined by the treating physician.</p>																																
<p>Drug interaction (significant interaction as outlined in BNF, please see BNF and SPC for more detail)</p>	<p>Rivaroxaban has the following interaction information:</p> <table border="1" data-bbox="336 568 1465 1462"> <tr> <td>Anticoagulants</td> <td>increased risk of haemorrhage when rivaroxaban given with other anticoagulants (avoid concomitant use except when switching with other anticoagulants or using heparin to maintain catheter patency)</td> </tr> <tr> <td>Carbamazepine</td> <td>plasma concentration of rivaroxaban possibly reduced by carbamazepine —manufacturer of rivaroxaban advises monitor for signs of thrombosis</td> </tr> <tr> <td>Cobicistat</td> <td>anticoagulant effect of rivaroxaban possibly enhanced by cobicistat —avoid concomitant use</td> </tr> <tr> <td>Fosphenytoin</td> <td>plasma concentration of rivaroxaban possibly reduced by fosphenytoin —manufacturer of rivaroxaban advises monitor for signs of thrombosis</td> </tr> <tr> <td>Ketoconazole</td> <td>plasma concentration of rivaroxaban increased by ketoconazole —avoid concomitant use</td> </tr> <tr> <td>Phenobarbital</td> <td>plasma concentration of rivaroxaban possibly reduced by phenobarbital —manufacturer of rivaroxaban advises monitor for signs of thrombosis</td> </tr> <tr> <td>Phenytoin</td> <td>plasma concentration of rivaroxaban possibly reduced by phenytoin —manufacturer of rivaroxaban advises monitor for signs of thrombosis</td> </tr> <tr> <td>Primidone</td> <td>plasma concentration of rivaroxaban possibly reduced by primidone —manufacturer of rivaroxaban advises monitor for signs of thrombosis</td> </tr> <tr> <td>Rifampicin</td> <td>plasma concentration of rivaroxaban reduced by rifampicin —manufacturer of rivaroxaban advises monitor for signs of thrombosis</td> </tr> <tr> <td>Ritonavir</td> <td>plasma concentration of rivaroxaban increased by ritonavir —avoid concomitant use</td> </tr> <tr> <td>St John's Wort</td> <td>plasma concentration of rivaroxaban possibly reduced by St John's wort —manufacturer of rivaroxaban advises monitor for signs of thrombosis</td> </tr> </table> <p>Rivaroxaban belongs to Anticoagulants and will have the following interactions:</p> <table border="1" data-bbox="336 1491 1465 1995"> <tr> <td>Apixaban</td> <td>increased risk of haemorrhage when other anticoagulants given with apixaban (avoid concomitant use except when switching with other anticoagulants or using heparin to maintain catheter patency)</td> </tr> <tr> <td>Dabigatran</td> <td>increased risk of haemorrhage when other anticoagulants given with dabigatran (avoid concomitant use except when switching with other anticoagulants or using heparin to maintain catheter patency)</td> </tr> <tr> <td>Diclofenac</td> <td>increased risk of haemorrhage when anticoagulants given with <i>intravenous</i> diclofenac (avoid concomitant use, including low-dose heparins)</td> </tr> <tr> <td>Ketorolac</td> <td>increased risk of haemorrhage when anticoagulants given with ketorolac (avoid concomitant use, including low-dose heparins)</td> </tr> <tr> <td>Rivaroxaban</td> <td>increased risk of haemorrhage when other anticoagulants given with rivaroxaban (avoid concomitant use except when switching with other anticoagulants or using heparin to maintain catheter patency)</td> </tr> </table>	Anticoagulants	increased risk of haemorrhage when rivaroxaban given with other anticoagulants (avoid concomitant use except when switching with other anticoagulants or using heparin to maintain catheter patency)	Carbamazepine	plasma concentration of rivaroxaban possibly reduced by carbamazepine —manufacturer of rivaroxaban advises monitor for signs of thrombosis	Cobicistat	anticoagulant effect of rivaroxaban possibly enhanced by cobicistat —avoid concomitant use	Fosphenytoin	plasma concentration of rivaroxaban possibly reduced by fosphenytoin —manufacturer of rivaroxaban advises monitor for signs of thrombosis	Ketoconazole	plasma concentration of rivaroxaban increased by ketoconazole —avoid concomitant use	Phenobarbital	plasma concentration of rivaroxaban possibly reduced by phenobarbital —manufacturer of rivaroxaban advises monitor for signs of thrombosis	Phenytoin	plasma concentration of rivaroxaban possibly reduced by phenytoin —manufacturer of rivaroxaban advises monitor for signs of thrombosis	Primidone	plasma concentration of rivaroxaban possibly reduced by primidone —manufacturer of rivaroxaban advises monitor for signs of thrombosis	Rifampicin	plasma concentration of rivaroxaban reduced by rifampicin —manufacturer of rivaroxaban advises monitor for signs of thrombosis	Ritonavir	plasma concentration of rivaroxaban increased by ritonavir —avoid concomitant use	St John's Wort	plasma concentration of rivaroxaban possibly reduced by St John's wort —manufacturer of rivaroxaban advises monitor for signs of thrombosis	Apixaban	increased risk of haemorrhage when other anticoagulants given with apixaban (avoid concomitant use except when switching with other anticoagulants or using heparin to maintain catheter patency)	Dabigatran	increased risk of haemorrhage when other anticoagulants given with dabigatran (avoid concomitant use except when switching with other anticoagulants or using heparin to maintain catheter patency)	Diclofenac	increased risk of haemorrhage when anticoagulants given with <i>intravenous</i> diclofenac (avoid concomitant use, including low-dose heparins)	Ketorolac	increased risk of haemorrhage when anticoagulants given with ketorolac (avoid concomitant use, including low-dose heparins)	Rivaroxaban	increased risk of haemorrhage when other anticoagulants given with rivaroxaban (avoid concomitant use except when switching with other anticoagulants or using heparin to maintain catheter patency)
Anticoagulants	increased risk of haemorrhage when rivaroxaban given with other anticoagulants (avoid concomitant use except when switching with other anticoagulants or using heparin to maintain catheter patency)																																
Carbamazepine	plasma concentration of rivaroxaban possibly reduced by carbamazepine —manufacturer of rivaroxaban advises monitor for signs of thrombosis																																
Cobicistat	anticoagulant effect of rivaroxaban possibly enhanced by cobicistat —avoid concomitant use																																
Fosphenytoin	plasma concentration of rivaroxaban possibly reduced by fosphenytoin —manufacturer of rivaroxaban advises monitor for signs of thrombosis																																
Ketoconazole	plasma concentration of rivaroxaban increased by ketoconazole —avoid concomitant use																																
Phenobarbital	plasma concentration of rivaroxaban possibly reduced by phenobarbital —manufacturer of rivaroxaban advises monitor for signs of thrombosis																																
Phenytoin	plasma concentration of rivaroxaban possibly reduced by phenytoin —manufacturer of rivaroxaban advises monitor for signs of thrombosis																																
Primidone	plasma concentration of rivaroxaban possibly reduced by primidone —manufacturer of rivaroxaban advises monitor for signs of thrombosis																																
Rifampicin	plasma concentration of rivaroxaban reduced by rifampicin —manufacturer of rivaroxaban advises monitor for signs of thrombosis																																
Ritonavir	plasma concentration of rivaroxaban increased by ritonavir —avoid concomitant use																																
St John's Wort	plasma concentration of rivaroxaban possibly reduced by St John's wort —manufacturer of rivaroxaban advises monitor for signs of thrombosis																																
Apixaban	increased risk of haemorrhage when other anticoagulants given with apixaban (avoid concomitant use except when switching with other anticoagulants or using heparin to maintain catheter patency)																																
Dabigatran	increased risk of haemorrhage when other anticoagulants given with dabigatran (avoid concomitant use except when switching with other anticoagulants or using heparin to maintain catheter patency)																																
Diclofenac	increased risk of haemorrhage when anticoagulants given with <i>intravenous</i> diclofenac (avoid concomitant use, including low-dose heparins)																																
Ketorolac	increased risk of haemorrhage when anticoagulants given with ketorolac (avoid concomitant use, including low-dose heparins)																																
Rivaroxaban	increased risk of haemorrhage when other anticoagulants given with rivaroxaban (avoid concomitant use except when switching with other anticoagulants or using heparin to maintain catheter patency)																																

Pre-treatment test results	Specialists please complete the information in table below:	
	Date of test	
	eGFR	
The patient has been informed of the need for annual (or more frequent if clinically appropriate) renal function tests in order to assess suitability for ongoing treatment. <input type="checkbox"/>		

Guidance on initiation (to be completed by the specialist)

Initiation dose:	The recommended dose for the initial treatment of acute DVT or PE is 15 mg twice daily for the first three weeks followed by 20 mg once daily for the continued treatment and prevention of recurrent DVT and PE, as indicated in the table below.											
		Dosing schedule	Maximum daily dose									
	Day 1-21	15 mg twice daily	30 mg									
	The duration of therapy should be individualised after careful assessment of the treatment benefit against the risk for bleeding. Short duration of therapy (at least 3 months) should be based on transient risk factors (e.g. recent surgery, trauma, immobilisation) and longer durations should be based on permanent risk factors or idiopathic DVT or PE											
	<table border="1"> <thead> <tr> <th>Renal Impairment</th> <th>Recommended dose</th> </tr> </thead> <tbody> <tr> <td>Mild (Creatinine clearance 50-80 ml/min)</td> <td>No dose adjustment is necessary</td> </tr> <tr> <td>Moderate (Creatinine clearance 30-49 ml/min)</td> <td>15 mg twice daily for the first 3 weeks. Thereafter, the recommended dose is 20 mg once daily</td> </tr> <tr> <td>Severe (Creatinine clearance 15-29 ml/min)</td> <td>Use rivaroxaban with caution in these patients</td> </tr> <tr> <td>Creatinine clearance < 15 ml/min</td> <td>Rivaroxaban not recommended</td> </tr> </tbody> </table>		Renal Impairment	Recommended dose	Mild (Creatinine clearance 50-80 ml/min)	No dose adjustment is necessary	Moderate (Creatinine clearance 30-49 ml/min)	15 mg twice daily for the first 3 weeks. Thereafter, the recommended dose is 20 mg once daily	Severe (Creatinine clearance 15-29 ml/min)	Use rivaroxaban with caution in these patients	Creatinine clearance < 15 ml/min	Rivaroxaban not recommended
Renal Impairment	Recommended dose											
Mild (Creatinine clearance 50-80 ml/min)	No dose adjustment is necessary											
Moderate (Creatinine clearance 30-49 ml/min)	15 mg twice daily for the first 3 weeks. Thereafter, the recommended dose is 20 mg once daily											
Severe (Creatinine clearance 15-29 ml/min)	Use rivaroxaban with caution in these patients											
Creatinine clearance < 15 ml/min	Rivaroxaban not recommended											
	A reduction of the dose from 20 mg once daily to 15 mg once daily should be considered if the patient's assessed risk for bleeding outweighs the risk for recurrent DVT and PE. The recommendation for the use of 15 mg is based on PK modelling and has not been studied in this clinical setting											
	Recommendation:- GP to add an end/review date on the directions and patients notes											
Specialist recommendations	Specialist to complete											
Continuation dose	Appropriate renal and hepatic function, assessment of bleeding risk, and compliance confirmed											
		Dosing schedule	Maximum daily dose									
	Day 22 and onwards	20 mg once daily	20 mg									
Additional info:	<ul style="list-style-type: none"> There is no known antidote to rivaroxaban. The tablets are to be taken with food. For patients who are unable to swallow whole tablets, rivaroxaban tablets may be crushed and mixed with water or apple puree immediately prior to use and administered orally. After the administration of the crushed tablets, the dose should be immediately followed by food. The crushed rivaroxaban tablet may also be given through gastric tubes after confirmation of the correct gastric placement of the tube. The crushed tablet should be administered in a small amount of water via a gastric tube after which it should be flushed with water. After the administration of the crushed tablets, the dose should be immediately followed by food. Rivaroxaban can be transferred to "monitored dose systems". Tablets must be swallowed whole. A liquid formulation is not available. Rivaroxaban ▼ is a black triangle drug. All suspected adverse effects should be reported to the CHM www.yellowcard.gov.uk 											
Monitoring:	Deterioration of renal function can significantly increase plasma concentration. Renal function should be assessed in all patients before starting rivaroxaban and at least once a year or more frequently as needed in clinical situations when it is suspected that the renal function could decline or deteriorate. The patient should be questioned periodically regarding any abnormal bleeding such as nosebleeds and encouraged to report any such events to the GP.											

Suggested Criteria for Continuation or Discontinuation (to be completed by the specialist)

Assessment of Efficacy										
Frequency	At routine appointments but at least annually									
Location	GP practice									
Method (what tests are required)	Renal and hepatic function tests Discussion with patient regarding compliance and any factors that may affect compliance (i.e. need for monitored dose system or swallowing difficulties) Reassess bleeding risk, including risk of falls, and use of medication associated with gastro-intestinal bleeding Review hepatic function									
Test results and action	Renal function <ul style="list-style-type: none"> Mild to moderate renal impairment: No dosage adjustment necessary Severe renal impairment (creatinine clearance 15-29 ml/min): Use with caution – seek specialist advice Creatinine clearance < 15 ml/min: Discontinue and seek specialist advice Compliance <ul style="list-style-type: none"> As indicated Reassessment of bleeding risk <ul style="list-style-type: none"> As indicated. If elevated from initiation, seek specialist advice. Hepatic function <ul style="list-style-type: none"> Discontinue if patient has developed hepatic disease associated with coagulopathy and clinically relevant bleeding risk 									
Continuation Criteria	Appropriate renal and hepatic function, assessment of bleeding risk, and compliance confirmed									
Discontinuation Criteria	When recommended duration of treatment reached following review. <ul style="list-style-type: none"> Renal function – CrCl <15 ml/min – discontinue CrCl 15-49 ml/min – reconsider use and dose - see dose section above Poor compliance Unacceptable bleeding risk Severe hepatic impairment Use with interacting medication with significant interactions as SPC. Recommended course completed. 									
Follow up action	Specialist to complete									
Shared Care read code	In the patients notes, using the appropriate Read Code listed below, denote that the patient is receiving treatment under a shared care agreement <table border="1" data-bbox="359 1350 1390 1438"> <thead> <tr> <th>GP Prescribing System</th> <th>Read Code</th> <th>Description</th> </tr> </thead> <tbody> <tr> <td>EMIS and Vision</td> <td>8BM5.00</td> <td>Shared care prescribing</td> </tr> <tr> <td>SystemOne</td> <td>XaB58</td> <td>Shared care</td> </tr> </tbody> </table>	GP Prescribing System	Read Code	Description	EMIS and Vision	8BM5.00	Shared care prescribing	SystemOne	XaB58	Shared care
GP Prescribing System	Read Code	Description								
EMIS and Vision	8BM5.00	Shared care prescribing								
SystemOne	XaB58	Shared care								